虚拟现实疼痛心理治疗用于癌性神经病理性疼痛的可行性:一项预试验随机对照试验
该预试验随机对照研究评估了定制虚拟现实疼痛治疗软件对癌性神经病理性疼痛患者的可行性、可接受性、招募率和晕动症风险。87例合格患者中招募39例(47%),随机分为干预组(20例)和对照组(19例)。干预组报告更少晕动症并耐受所有治疗,1个月和3个月随访时口服吗啡等效日剂量、疼痛严重程度和疼痛干扰有下降趋势,但组间生活质量无显著变化。
要点
- 定制虚拟现实疼痛治疗软件对癌性神经病理性疼痛患者可行且可接受。
- 既存头晕和恶心与晕动症风险显著相关。
- 干预组在阿片用量和疼痛评分方面呈现下降趋势。
核心结论
- 该虚拟现实疼痛治疗软件对癌性神经病理性疼痛患者可行且可接受。
- 结果为设计确定性多中心随机对照试验提供依据。
研究设计与样本
- 随机对照预试验,87例合格癌症神经病理性疼痛患者中招募39例(47%)。
- 干预组20例接受定制虚拟现实疼痛治疗软件,对照组19例观看虚拟现实视频。
- 4例在3个月随访前退出,均对照组。
主要发现
- 既存头晕(Spearman ρ 0.37,p = 0.02)和既存恶心(Spearman ρ 0.81,p < 0.001)与两组晕动症风险显著相关。
- 干预组报告更少晕动症,耐受并完成所有治疗。
- 1个月和3个月随访时,干预组口服吗啡等效日剂量变化为-8 mg和-4 mg,对照组为0 mg和+15 mg。
- 1个月和3个月随访时,干预组改良简明疼痛量表疼痛严重程度变化为-0.4和-0.8,对照组为+0.4和-0.3。
- 1个月和3个月随访时,干预组疼痛干扰变化为-0.9和-1.8,对照组为-0.2和-0.3。
关键数值与推荐
- 招募率47%(39/87)。
- 既存头晕与晕动症风险Spearman ρ 0.37,p = 0.02。
- 既存恶心与晕动症风险Spearman ρ 0.81,p < 0.001。
临床怎么用
- 该虚拟现实疼痛治疗软件可作为癌性神经病理性疼痛患者的非药物管理选项。
- 实施前应评估患者既存头晕和恶心以降低晕动症风险。
局限性
- 预试验样本量小,主要评估可行性。
- 4例退出均来自对照组。
- 临床结局为次要目标,趋势需确定性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Virtual reality-delivered psychological therapies have recently been investigated as non-pharmacological management for acute and chronic pain. However, no virtual reality pain therapy software existed that met the needs of cancer patients with neuropathic pain. We created a bespoke virtual reality-delivered pain therapy software programme to help cancer patients manage neuropathic pain incorporating guided visualisation and progressive muscle relaxation techniques, whilst minimising the risk of cybersickness in this vulnerable patient population. This randomised controlled pilot study evaluated the feasibility, acceptability, recruitment rates and risk of cybersickness of this pain therapy software programme. Clinical outcomes including opioid consumption, pain severity, pain interference and global quality of life scores were secondary aims. Of 87 eligible cancer patients with neuropathic pain, 39 were recruited (47%), allocated to either the intervention (20 patients, virtual reality pain therapy software programme) or control (19 patients, viewing virtual reality videos). Four patients withdrew before the 3-month follow-up (all in the control group). Pre-existing dizziness (Spearman ρ 0.37, p = 0.02) and pre-existing nausea (Spearman ρ 0.81, p < 0.001) were significantly associated with risk of cybersickness in both groups. Patients in the intervention group reported less cybersickness, as well as tolerated and completed all therapy sessions. At 1- and 3-month follow-up, there were trends in the intervention group towards reductions in: oral morphine equivalent daily dose opioid consumption (-8 mg and -4 mg; vs. control: 0 mg and +15 mg respectively); modified Brief Pain Inventory pain severity (-0.4, -0.8; vs. control +0.4, -0.3); and pain interference (-0.9, -1.8; vs. control -0.2, -0.3) scores. The global quality of life subscale from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 was not significantly changed between groups at 1 and 3 months (intervention: -5, -8; vs. control: +3, +4). This newly created virtual reality-delivered pain therapy software programme was shown to be feasible and acceptable to cancer patients with neuropathic pain. These results will aid the design of a definitive multicentre randomised controlled trial.
引用
- Chuan A, Hatty M, Shelley M, et al. Feasibility of virtual reality-delivered pain psychology therapy for cancer-related neuropathic pain: a pilot randomised controlled trial. Anaesthesia. 2023. PMID: 36734021. doi:10.1111/anae.15971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。